BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 11122868)

  • 1. New approaches to treatment of metastatic bladder cancer.
    Edelman MJ
    Curr Oncol Rep; 2000 Sep; 2(5):379-85. PubMed ID: 11122868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and future perspectives in advanced bladder cancer: is there a new standard?
    von der Maase H
    Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New chemotherapy regimens for advanced bladder cancer.
    Fagbemi SO; Stadler WM
    Semin Urol Oncol; 1998 Feb; 16(1):23-9. PubMed ID: 9508079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.
    von der Maase H; Hansen SW; Roberts JT; Dogliotti L; Oliver T; Moore MJ; Bodrogi I; Albers P; Knuth A; Lippert CM; Kerbrat P; Sanchez Rovira P; Wersall P; Cleall SP; Roychowdhury DF; Tomlin I; Visseren-Grul CM; Conte PF
    J Clin Oncol; 2000 Sep; 18(17):3068-77. PubMed ID: 11001674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
    Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
    Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
    Shelley M; Cleves A; Wilt TJ; Mason M
    Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium.
    Bellmunt J; Albiol S; de Olano AR; Pujadas J; Maroto P;
    Ann Oncol; 2006 May; 17 Suppl 5():v113-7. PubMed ID: 16807437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world.
    Roth BJ; Bajorin DF
    J Urol; 1995 Mar; 153(3 Pt 2):894-900. PubMed ID: 7853569
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer.
    Roberts JT; von der Maase H; Sengeløv L; Conte PF; Dogliotti L; Oliver T; Moore MJ; Zimmermann A; Arning M
    Ann Oncol; 2006 May; 17 Suppl 5():v118-22. PubMed ID: 16807438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy for advanced bladder carcinoma: new molecules and regimens.
    Abi-Aad AS
    Acta Urol Belg; 1996 May; 64(2):43-5. PubMed ID: 8701810
    [No Abstract]   [Full Text] [Related]  

  • 11. [Gemcitabine/cisplatin vs. MVAC. 5 year survival outcome of the phase III study of chemotherapy of advanced urothelial carcinoma in Germany].
    Lehmann J; Retz M; Steiner G; Albers P; Jaeger E; Knuth A; Lippert C; Koser M; Stockamp K; Otto C; Melchior H; Fassmann C; Potratz C; Loch T; Derigs HG; Becker T; Kälble T; Piechota HJ; Hertle L; Weinknecht S; Weissbach L; Al-Mwalad M; Hamza A; Henss H; Brkovic D; Pomer S; Roloff J; Walz P; Muschter R; Tunn U; Winter E; Bub P; Kaldenbach U; Roth S; Brauers A; Jakse G; Richter AE; Wirth M; Hartlapp J; Van Ahlen H; Stöckle M
    Urologe A; 2003 Aug; 42(8):1074-86. PubMed ID: 14513232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder.
    Yeshchina O; Badalato GM; Wosnitzer MS; Hruby G; RoyChoudhury A; Benson MC; Petrylak DP; McKiernan JM
    Urology; 2012 Feb; 79(2):384-90. PubMed ID: 22196406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New chemotherapy combinations for advanced bladder cancer.
    Bellmunt J; Albiol S
    Curr Opin Urol; 2001 Sep; 11(5):517-22. PubMed ID: 11493774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic chemotherapy of transitional cell carcinoma of the urothelium.
    Brinkley WM; Torti FM
    Semin Surg Oncol; 1997; 13(5):365-75. PubMed ID: 9259093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
    Galsky MD; Pal SK; Chowdhury S; Harshman LC; Crabb SJ; Wong YN; Yu EY; Powles T; Moshier EL; Ladoire S; Hussain SA; Agarwal N; Vaishampayan UN; Recine F; Berthold D; Necchi A; Theodore C; Milowsky MI; Bellmunt J; Rosenberg JE;
    Cancer; 2015 Aug; 121(15):2586-93. PubMed ID: 25872978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine-cisplatin and high dose-intensity MVAC.
    Lee Y; Kim YS; Hong B; Cho YM; Lee JL
    J Cancer Res Clin Oncol; 2021 Nov; 147(11):3421-3429. PubMed ID: 33715088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Active chemotherapy with gemcitabine, carboplatin and docetaxel for three patients with MVAC-resistant liver metastasis of urothelial carcinoma].
    Inoue T; Ohyama C; Horikawa Y; Togashi H; Matsuura S; Tsuchiya N; Satoh S; Sato K; Habuchi T; Saito S; Hoshi S; Arai Y; Kato T
    Hinyokika Kiyo; 2004 Apr; 50(4):273-7. PubMed ID: 15188623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-line treatment of advanced transitional cell carcinoma of the urothelial tract.
    Sternberg CN
    Curr Opin Urol; 2001 Sep; 11(5):523-9. PubMed ID: 11493775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Relative efficacy of neoadjuvant gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management for muscle-invasive bladder cancer].
    Kawamura N; Matsushita M; Okada T; Ujike T; Nin M; Tsujihata M
    Hinyokika Kiyo; 2013 May; 59(5):277-81. PubMed ID: 23719134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.
    von der Maase H; Sengelov L; Roberts JT; Ricci S; Dogliotti L; Oliver T; Moore MJ; Zimmermann A; Arning M
    J Clin Oncol; 2005 Jul; 23(21):4602-8. PubMed ID: 16034041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.